Prologue Medicines
Prologue is a biopharmaceutical company focused on creating transformative medicines by leveraging viral evolution. They utilize their proprietary DELVE™ Platform to systematically discover and evaluate viral proteins for their therapeutic potential. By exploring the viral proteome, Prologue aims to develop new programmable medicines with enhanced properties that go beyond the capabilities of human proteins, addressing unmet medical needs in various diseases. The company was founded by Flagship Pioneering.
Prologue Medicines
Prologue is a biopharmaceutical company focused on creating transformative medicines by leveraging viral evolution. They utilize their proprietary DELVE™ Platform to systematically discover and evaluate viral proteins for their therapeutic potential. By exploring the viral proteome, Prologue aims to develop new programmable medicines with enhanced properties that go beyond the capabilities of human proteins, addressing unmet medical needs in various diseases. The company was founded by Flagship Pioneering.
TL;DR
Headquarters: Cambridge, Massachusetts
Core technology: DELVE™ platform (viral proteome discovery & engineering)
Founded / origin: Founded by Flagship Pioneering (origination cited as 2021)
Early funding: $50M initial commitment; Series A led by Flagship Pioneering
Employee count: ~26
Company Overview
Problem Domain
Therapeutic discovery and development targeting immunology, oncology, and metabolic diseases by leveraging viral protein features.
Founded
2021
Industry
Biotechnology / Biopharmaceuticals
Funding Track Record
50000000.00 USD
Initial Flagship commitment at public launch
Investor Signal
“Flagship Pioneering lead investor and founding sponsor”